ResearCh articlE

Antibacterial activity of *Xenorhabdus* and *Photorhabdus* isolated from entomopathogenic nematodes against antibiotic-resistant bacteria

Paramaporn Muangpat¹, Manawat Suwannaroj¹, Thatcha Yimthin², Chamaiporn Fukruksa¹, Sutthirat Sitthisak¹, Narisara Chantratita², Apichat Vitta¹,³,⁴, Aunchalee Thanwisai¹,³,⁴*¹

¹ Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand, ² Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, ³ Centre of Excellence in Medical Biotechnology (CEMB), Faculty of Medical Science, Naresuan University, Phitsanulok, Thailand, ⁴ Center of Excellent for Biodiversity, Faculty of Science, Naresuan University, Phitsanulok, Thailand

* aunchalee@nu.ac.th

Open access

Citation: Muangpat P, Suwannaroj M, Yimthin T, Fukruksa C, Sitthisak S, Chantratita N, et al. (2020) Antibacterial activity of *Xenorhabdus* and *Photorhabdus* isolated from entomopathogenic nematodes against antibiotic-resistant bacteria. PLoS ONE 15(6): e0234129. https://doi.org/10.1371/journal.pone.0234129

Editor: Filippo Giarratana, University of Messina, ITALY

Received: March 14, 2020
Accepted: May 19, 2020
Published: June 5, 2020

Copyright: © 2020 Muangpat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by The National Research Council of Thailand through Naresuan University (Grant Number R2562B083). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

abstract

*Xenorhabdus* and *Photorhabdus*, symbiotically associated with entomopathogenic nematodes (EPNs), produce a range of antimicrobial compounds. The objective of this study is to identify *Xenorhabdus* and *Photorhabdus* and their EPNs hosts, which were isolated from soil samples from Saraburi province, and study their antibacterial activity against 15 strains of drug-resistant bacteria. Fourteen isolates (6.1%), consisting of six *Xenorhabdus* isolates and eight *Photorhabdus* isolates, were obtained from 230 soil samples. Based on the BLASTN search incorporating the phylogenetic analysis of a partial recA gene, all six isolates of *Xenorhabdus* were found to be identical and closely related to *X. stockiae*. Five isolates of *Photorhabdus* were found to be identical and closely related to *P. luminescens* subsp. *akhurstii*. Two isolates of *Photorhabdus* were found to be identical and closely related to *P. luminescens* subsp. *hainanensis*. The remaining isolate of *Photorhabdus* was found to be identical to *P. asymbiotica* subsp. *australis*. The bacterial extracts from *P. luminescens* subsp. *akhurstii* showed strong inhibition the growth of *S. aureus* strain PB36 (MRSA) by disk diffusion, minimal inhibitory concentration, and minimal bactericidal concentration assay. The combination between each extract from *Xenorhabdus/Photorhabdus* and oxacillin or vancomycin against *S. aureus* strain PB36 (MRSA) exhibited no interaction on checkerboard assay. Moreover, killing curve assay of *P. luminescens* subsp. *akhurstii* extracts against *S. aureus* strain PB36 exhibited a steady reduction of $10^5$ CFU/ml to $10^3$ CFU/ml within 30 min. This study demonstrates that *Xenorhabdus* and *Photorhabdus* showed antibacterial activity. This finding may be useful for further research on antibiotic production.
Introduction

Antibiotic-resistant bacteria have become an emerging public health problem. *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli*, *Staphylococcus aureus*, *Acinetobacter baumannii*, and *Enterococcus faecalis* are the major sources of antibiotic-resistant bacteria [1]. These bacteria develop new resistance mechanisms with the emergence and the spread of the disease. This leads to higher cost of healthcare, longer duration of illness, use of more expensive drugs, and the success of prevention and treatment. Antibiotics are used as a general antimicrobial therapy to effectively treat infections. At present, the number of antibiotics effective against drug resistance is declining, predisposing us toward a future without effective antibiotics [2–5]. It is difficult to get accurate estimates of antimicrobial-resistant bacterial infections which are predicted lead to nearly 10 million deaths per year by 2050 [6]. Therefore, alternative treatments are needed against antibiotic-resistant bacteria. Biological compounds from natural or bacterial resources are one such alternative approach. *Xenorhabdus* and *Photorhabdus*, the symbiotic bacteria associated with entomopathogenic nematodes (EPNs), have been reported to be bacterial resources for the production of antimicrobial compounds. Their cell suspension and metabolite compound activities effectively inhibit the growth of *Staphylococcus pyogenes* and *S. aureus* [7,8], *Bacillus subtilis*, *Botrytis cinerea* [9], *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae* [10], *Fuscidialium effusions* [11], *Bacillus anthracis*, *Phytophthora capsici*, and *Rhizoctonia solani* [12].

*Xenorhabdus* and *Photorhabdus* are insect pathogenic Gram-negative bacilli belonging to the Enterobacteriaceae family that are intestinal symbionts of the infective juvenile (IJ) stage of nematodes in the families Steinernematidae and Heterorhabditidae, respectively. The IJ can penetrate the diverse insect hosts via natural openings, e.g., mouth, spiracle, and anus and enter to digestive tract and hemocoel of the hosts. Upon entry, the nematodes release their symbiotic bacteria into the insect hemolymph where the bacteria multiply. The presence of large numbers of the bacterial symbionts has result in death of the insect larvae within 24–48 h [13]. Within the hemocoel of insect carcass the bacteria grow to stationary phase while the nematodes develop and sexually reproduce. During the final stage of development, the bacteria are able to colonize the intestine of the next generation of the IJs, and then the IJs emerge from the insect carcass to search for a new insect host. Information regarding the association between EPNs and their symbiotic bacteria is scarcely reported in Thailand. The *Steinernema siamkayai* associated with *X. stockiae* was first described by Tailliez et al. [14]. Later, *H. indica*, in association with *P. luminescens*, was found in the Khon Kaen (northeastern Thailand) and Krabi (southern Thailand) provinces [15]. Diversity of association between symbiotic bacteria and EPNs has been reported: *X. stockiae* associated with *S. websterii*, *X. mirianiensis* lived with *S. kholisanae*, *P. luminescens* lived with *H. indica*, *H. baujardi*, *H. sp. SGgi* or *H. sp. SGmg3*, *P. asymbiotica* lived with *H. indica* [16], and *Xenorhabdus* sp. associated with *S. websterii* and was isolated from lower northern Thailand [17].

At the present, 26 species of *Xenorhabdus* and five species of *Photorhabdus* have been documented worldwide, together with approximately 100 species of EPNs [16–23]. These bacteria produce a broad range of secondary metabolites, including antimicrobial, insecticidal, and cytotoxic activities [8]. Antimicrobial compounds include benzaldehyde [12], 1-carbapen-2-em-3-carboxylic acid [10], 3, 5-dihydroxy-4-isopropylstilbene [9], 3-hydroxy-2-isopropyl-5-phenethylphenyl carbamate [24], 2-isopropyl-5-(3-phenyl-2-oxiran-1-ol) benzene-1,3-diol [25], and chaiyaphumine [26]. In the recent year, antibiotic-resistant bacteria are emerging with global spread leads to difficulties for the control of the disease. We expected that the crude extracts of *Xenorhabdus* or *Photorhabdus* combination with antibiotics could inhibit the growth of antibiotic-resistant bacteria. Natural products have been an unlimited source of...
biologically-active compound. Although several compounds have emerged from the process of drug discovery, many steps are needed to further carry on to achieve the goals and reduce the burden of antimicrobial-resistant bacteria. The US food and drug administration (FDA) has classified the main processes for drug development as follows: (1) discovery and development in the laboratory, (2) preclinical research in the laboratory and animal testing of the drugs, (3) clinical research in human for safety and efficacy, (4) FDA review for approval of data related to the drugs, and (5) FDA post-market safety monitoring when products are usable for the public [27].

Despite technological advances in pharmaceutical productions, there is still a need to identify new potential antibiotics against the antibiotic-resistant bacteria from different resources. The objective of this study was to study the antibacterial activities of *Xenorhabdus* and *Photorhabdus* against antibiotic-resistant bacteria. *Xenorhabdus* and *Photorhabdus*, associated with the EPNs collected from Saraburi province, were identified using molecular techniques. In addition, a phylogenetic tree of *Xenorhabdus* and *Photorhabdus* was constructed to determine their phylogenetic relationship.

**Materials and methods**

**Soil collection and EPNs isolation**

The Saraburi province in central Thailand was selected as the soil sampling site. Samples were taken from a diverse of habitats, for example, natural grassland, roadside verges, woodland, and bank of ponds and rivers. No specific permission was required for the collection of soil samples. For each site, 5 soil samples were randomly taken in an area of approximately 100 m² at a depth of 10–20 cm using a hand shovel. Approximately 500 g of each soil sample was placed into a plastic bag [16]. A total of 46 sites were sampled, and 230 soil samples were collected from the Mueang Saraburi, Phra Phutthabat, Kaeng Khoi, and Sao Hai districts. The EPNs were isolated from the soil samples using the *Galleria mellonella* baiting technique as described by Bedding and Akhurst [28]. White traps were used to isolate the emerging infective juvenile EPNs from the *G. mellonella* cadavers [29]. The larval nematodes were kept at 13–15°C in distilled water prior to molecular identification.

**Identification of EPNs**

PCR amplification and sequencing of a partial region of 28S rDNA gene or internal transcribed spacer (ITS) were performed according to Hominick et al. and Stock et al [30,31]. The primers TW81_F (5’-GTTTCCGTAGGTGAACCTGC-3’) and AB28_R (5’-ATATGCTTAAGTTCAGCGGGT-3’) were used to amplify a region of internal transcribed spacers for *Heterorhabditis*, while 539_F (5’GGATTTCCTTAGTAACTGCGAGTG-3’) and 535_R (5’TAGTCTTTTCGCCCTATACCCTT-3’) were used to amplify a region of 28S rDNA for *Sternernema*. The genomic DNA samples of nematodes were extracted using a protocol described previously in Thanwisai et al. [16]. The PCR conditions were as described in Thanwisai et al. and Vitta et al. [16,17]. The PCR components (30 μl) comprised of 7.5 μl of a DNA-extracted solution (approximately 200 μg), 0.6 μl of 200 μM dNTPs, 1.2 μl of 5μM each primer, 4.2 μl of 25 mM MgCl2, 3 μl of 10X buffer, 0.3 μl of 5 U/μl Tag polymerase, and 12 μl of distilled water. The cycling conditions for ITS were used as follows: one cycle of 95°C for 5 min, followed by 35 cycles of 94°C for 1 min, 50°C for 30 sec, 72°C for 1 min, and a final extension at 72°C for 7 min. The cycling conditions for 28s rDNA were used as follows: one cycle of 95°C for 5 min, followed by 35 cycles of 94°C for 1 min, 55°C for 30 sec, 72°C for 45 sec, and a final extension at 72°C for 7 min. Both PCR conditions were performed in the Applied Biosystems thermal cycler (Applied Biosystems™ Veriti™ thermal cycler, Pittsburgh, USA).
PCR products were visualized on ethidium bromide-stained agarose gel and purified using a Gel/PCR DNA Fragments Extraction Kit (Geneaid Biotech Ltd., Taiwan). Sequencing was performed by Macrogen Inc. (Korea). A BLASTN search was performed against a nucleotide database to identify EPN species (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). A similarity above 97% was considered as the same species.

**Isolation, identification, and phylogenetic tree of *Xenorhabdus* and *Photorhabdus***

*Xenorhabdus* and *Photorhabdus* were isolated from the haemolymph of dead *Galleria mellonella*, which was infected with EPNs. Approximately 1 μl of haemolymph was streaked on nutrient bromothymol blue triphenyltetrazolium chloride agar (NBTA) (HiMedia, Mumbai, India), which is a selective and differential medium. A dark green colony of *Photorhabdus* and a blue colony of *Xenorhabdus* were observed after incubation in the dark at room temperature for 3–4 days [16]. A single colony from each isolate was sub-cultured on NBTA. All the bacterial isolates were kept in a Luria Bertani broth (HiMedia, Mumbai, India) containing 20% glycerol at -40˚C.

Species identification and phylogenetic analysis of *Xenorhabdus* and *Photorhabdus* isolates were performed based on a partial recA sequence. Genomic DNA was extracted from a 3 ml LB overnight culture of *Xenorhabdus* and *Photorhabdus* using a Genomic DNA Mini Kit (Geneaid Biotech Ltd., Taiwan). A set of primers, recA_F (5’-GCTATTGATGAAAATAAAC-3’) and recA_R (5’- RATTTTRTCWCCRTTRTAGCT–3’), was used to amplify an 890 bp region of the recA gene [32]. A total volume of 30 μl PCR reagent contained 3 μl of DNA extract, 0.6 μl of 200 μM dNTPs, 1.2 μl of 5 μM of each primer, 4.2 μl of 25mM MgCl₂, 3 μl of 10X reaction buffer, 0.3 μl of 5U/ml Tag polymerase, and 12 μl of distilled water, as carried out in the Applied Biosystems thermal cycler (Applied Biosystems™ Veriti™ thermal cycler, Pittsburgh, USA) with PCR parameters and as described by Thanwisai et al. [16]. PCR products were visualized on ethidium bromide-stained agarose-gel electrophoresis and purified using a Gel/PCR DNA Fragment Extraction Kit (Geneaid Biotech Ltd., Taiwan). The purified PCR products were sequenced by Macrogen Inc. To identify *Xenorhabdus/Photorhabdus* into species level, BLASTN search against the NCBI nucleotide database (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) was performed using a partial recA gene. Multiple nucleotide sequences representing all the known species and subspecies of *Xenorhabdus* and *Photorhabdus* were downloaded from the NCBI database, aligned with the sequences from the study isolates, and trimmed to 588 bp using Clustal W included in MEGA software version 7.0. A phylogenetic tree was constructed by maximum likelihood (ML) and neighbor joining (NJ) with 1,000 bootstrap replicates using the Nearest-Neighbor-Interchange (NNI) and Tamura-Nei model by MEGA software version 7.0. Bayesian analysis was performed based on the Markov chain Monte Carlo method in MrBayes v3.2. The recA sequences were deposited in Genbank under the accession number MK478066 to MK478071 for six *Xenorhabdus* isolates and MK478072 to MK478079 for eight *Photorhabdus* isolates.

**Antibacterial activity of *Xenorhabdus* and *Photorhabdus* against antibiotic-resistant bacteria**

**Preparation of antibiotic-resistant bacteria.** The experiments involving antibiotic-resistant bacteria were approved by Naresuan University Institutional Biosafety Committee (NUIBC MI62-06-25). Fifteen strains of antibiotic-resistant bacteria, including *Acinetobacter baumannii* (four clinical strains), *Escherichia coli* (two clinical strains), *E. coli* ATCC35218, *Klebsiella pneumoniae* (two clinical strains), *K. pneumoniae* ATCC700603, *Enterococcus*...
*faecalis* ATCC51299, *Pseudomonas aeruginosa*, *Staphylococcus aureus* (two clinical strains), and *S. aureus* ATCC20475 were used as pathogens for antibacterial activity. These bacteria were streaked on Mueller–Hinton agar (MHA) and incubated at 37˚C for 24 h. A single colony was dissolved in 0.85% sodium chloride (NaCl), and the turbidity was adjusted to 0.5 McFarland standards. One hundred microliters of the bacterial suspension was swabbed on MHA for disk diffusion method [33].

**Screening of Xenorhabdus and Photorhabdus isolates.** To initially evaluate the antibacterial activity of whole cell culture of *Xenorhabdus* and *Photorhabdus* bacteria against antibiotic resistant bacteria, the *Xenorhabdus* and *Photorhabdus* isolates were cultured on NBTA for four days at room temperature. A single colony from each isolate was transferred into LB broth and cultured with shaking at room temperature for 48 h. The whole cell suspension of *Xenorhabdus* and *Photorhabdus* was used for the screening of antibacterial activity. Twenty μl of whole cell suspension was dropped on a Mueller–Hinton (MH) agar plated with antibiotic-resistant bacteria. The plates were then incubated at 37˚C for 24 h. A clear zone from the edge of growth colony of *Xenorhabdus* and *Photorhabdus* was read as positive. The *Xenorhabdus* and *Photorhabdus* isolates that showed potential inhibition of at least one antibiotic-resistant bacteria were selected for metabolic extraction in the disc sensitivity test.

**Bacterial extracts.** A single colony of *Xenorhabdus* and *Photorhabdus* on NBTA was transferred and cultured in a 1000 ml flask containing 500 ml LB. The culture was incubated at room temperature with shaking at 180 rpm for 72 h. For extraction, 1000 ml of ethyl acetate was added to the culture and mixed well. The flask was then allowed to stand at room temperature for 24 h. All bacterial extracts were concentrated using a rotary vacuum evaporator (Buchi, Flawil, Switzerland). The extraction was performed thrice to maximize the level of crude compounds. The extract was dried under laminar airflow and stored at -20˚C until it was used for the disk diffusion method.

**Disk diffusion method.** Bacterial extracts from *Xenorhabdus* and *Photorhabdus* were dissolved in dimethyl sulfoxide (DMSO) to a concentration 500 mg/ml. Ten microliters of the solution were dropped into a sterile 6 mm paper disc, which was then placed on the MHA plated with antibiotic-resistant bacteria. Antibiotic discs with vancomycin, tigecycline, ampicillin, cefazidime, and cefazidime/clavulanic acid were used as positive control and disc with DMSO was used as a negative control. The plates were then incubated at 37˚C for 24 h. The diameter of clear zone (millimeter), representing the zone of inhibition, was measured in millimeter using a ruler.

**Minimum Inhibitory Concentrations (MIC) and Minimal Bactericidal Concentrations (MBC).** Bacterial extracts with the most effective result in disk diffusion method were further evaluated by minimum inhibitory concentrations (MIC) using broth microdilution method. Two-fold serial dilutions of bacteria extract were performed in a 96-well micro titer plate. Antibiotic-resistant bacteria cultured, antibiotic-resistant bacteria cultured mixed with DMSO, and sterile Mueller–Hinton (MH) broth were used as control. Plates were incubated at 37˚C for 24 h. The MIC is defined as the lowest concentration of extract in which there is no visible growth of testing bacteria in the well. In addition, the minimum bactericidal concentrations (MBC) was evaluated. Ten microliters from each well of 96-well micro titer plates from MIC was sub-cultured onto the MHA plates. The plates were then incubated at 37˚C for 24 h. The lowest concentration of each extract without growth of bacteria was considered as MBC.

**Checkerboard determination of synergistic effect of combined drugs.** Bacterial extracts exhibiting highest MIC and MBC against *S. aureus* strain PB36 (clinical isolate) were further evaluated using Checkerboard assay. Antimicrobial combinations were performed following Teethaisong et al. [34]. The methods of bacterial culture and preparation of antibacterial agents were performed as described for the MIC broth microdilution. Fifty μl of Cation–
Mueller–Hinton broth (CaMHB) was transferred into each well of 96-well micro titer plate. The antibiotics (vancomycin and oxacillin) of the combination were two-fold serially diluted along the ordinate, while the bacterial extracts were diluted along the abscissa. Each well was inoculated with 100 μl of a S. aureus strain PB36 suspension (0.5 MacFarland). The plates were incubated at 37°C for 24 h. The MICs were determined as the lowest concentration drugs in combination with bacterial extracts. The fractional inhibitory concentration (FIC) index or FICI was calculated as follows: \( \text{FIC index} = \text{FIC A} + \text{FIC B} \), where FIC A is the MIC of drug A in the combination/MIC of drug A alone, and FIC B is the MIC of drug B in the combination/MIC of drug B alone. The combination is considered synergistic when FICI \( \leq 0.5 \), no interaction when the FICI is 0.5–4.0, and antagonism when the FICI is > 4.0.

**Time killing assay.** The bacterial extract at 1× MIC, was mixed with a culture of S. aureus strain PB36 (MRSA) in the CaMHB and then adjusted to a final inoculum of \( 10^5 \) CFU/ml. The mixture was diluted and counted using a drop plate technique on MHA at following time point 0, 30 min, 1h, 2h, 3h 4h, 5h, 6 h and 24 h. The plate was then incubated at 37°C. The growing colonies were counted after 24 h. The variability of S. aureus strain PB36 (MRSA) treated with the bacterial extracts at different time was statistically analyzed by one-way analysis of variance (ANOVA) followed by multiple comparison, using the Bonferroni correction (STATA version 13). The \( P \)-value lower than 0.05 was considered as significant difference.

**Results**

**EPNs isolation and identification**

A total of 46 sample sites with 230 soil samples yielded 14 isolates of EPNs belonging to the genus *Steinernema* (six isolates) and *Heterorhabditis* (eight isolates). After the BLASTN search, six isolates of *Steinernema* were identified as *S. surkhetense* (99% identity) while two isolates of *Heterorhabditis* were identified as *H. indica* (99% identity). The remaining six isolates of *Heterorhabditis* were unidentified at the species level because of the low amount of genomic DNA.

**Xenorhabdus and Photorhabdus isolation and identification**

Six isolates of *Xenorhabdus* and eight isolates of *Photorhabdus* were isolated from the 14 EPNs isolates. The colony of *Xenorhabdus* was blue on NBTA agar, while *Photorhabdus* was green. Based on a region of the *recA* gene, *Xenorhabdus* was identified as *X. stockiae* (six isolates with 98–99% identity), while *Photorhabdus* was identified as *Photorhabdus luminescens* subsp. *akhurstii* (five isolates with 98% identity), *Photorhabdus luminescens* subsp. *hainanensis* (two isolates with 98–99%), and *Photorhabdus azymbiotica* subsp. *australis* (one isolate with 100% identity).

**Phylogenetic tree of Xenorhabdus and Photorhabdus**

Maximum likelihood (ML) tree of *Xenorhabdus* revealed that six isolates of *Xenorhabdus* in the present study were clustered with *X. stockiae* strain TH01. The maximum likelihood tree of seven isolates of *Photorhabdus* was grouped with *Photorhabdus luminescens* subsp. *hainanensis* strain C8404 and *Photorhabdus luminescens* subsp. *akhurstii* strain FRG04, while one isolate of *Photorhabdus* was placed in the group of *Photorhabdus asymbiotica* subsp. *australis* strain 9802892 (Fig 1).

**Antibacterial activity**

Screening of whole cell culture and the extracts by the disk diffusion method demonstrated that seven isolates of *Xenorhabdus* and *Photorhabdus* showed the potential inhibition of the...
growth of antibiotic-resistant bacteria (Table 1 and Fig 2). Four bacterial extracts, including X. stockiae (bSBR31.4_TH) and P. luminescens subsp. akhurstii stains bSBR11.1_TH, bSBR12.3_TH, and bSBR36.2_TH could inhibit S. aureus ATCC20475, S. aureus strain PB36 (MRSA), S. aureus strain PB57 (MRSA), A. baumannii strain AB320 (extensively drug resistant or XDR), A. baumannii strain AB321 (multi drug resistant or MDR), A. baumannii strain AB322 (MDR), and E. faecalis ATCC51299. In contrast, three bacterial extracts from X. stockiae stains bSBR4.5_TH, bSBR18.3_TH, and bSBR19.1_TH were unable to inhibit any antibiotic-resistant bacteria by the disk diffusion method. P. luminescens subsp. akhurstii bSBR36.2_TH showed the most board-range inhibition of up to 11 strains of antibiotic-resistant bacteria. These included A. baumannii strain AB320 (XDR), A. baumannii strain AB321 (MDR), A. baumannii strain AB322 (MDR), A. baumannii strain AB324 (XDR), S. aureus ATCC20475, S. aureus strain PB36 (meticillin-resistant S. aureus or MRSA), S. aureus strain PB57 (MRSA), E. coli strain PB1 (Extended Spectrum Beta- Lactamase or ESBL and MDR), E. coli strain PB231 (ESBL and Carbapenem-resistant Enterobacteriaceae or CRE), P. aeruginosa strain PB30 (MDR), and E. faecalis ATCC51299.

Based on the result of MIC and MBC, one isolate of X. stockiae and three isolates of P. luminescens subsp. akhurstii were further evaluated against five strains of antibiotic-resistant bacteria, including S. aureus strain PB36 (MRSA), S. aureus strain PB57 (MRSA), A. baumannii strain AB321 (MDR), A. baumannii strain AB322 (MDR), and E. faecalis ATCC51299. The inhibitory effect of bacterial extracts on these antibiotic-resistant bacteria showed the MICS and MBCs ranging from 7.81 to 0.98 mg/ml (Table 2).

In the checkerboard assay, the results of the combination against S. aureus strain PB36 (MRSA) are shown in Table 3. Based on the FIC index calculation, the combination of oxacillin and bacterial extracts exhibited no interaction with FIC index 0.53 and 1. Moreover, the combination of vancomycin and bacterial extracts exhibited no interaction with FIC index at 1.

Fig 3 shows time-kill curves for bacterial extracts against S. aureus strain PB36 (MRSA). Photorhabdus extracts of strains bSBR11.1_TH, bSBR12.3_TH, and bSBR36.2_TH exhibited a steady reduction of S. aureus strain PB36 (MRSA) from 10^5 CFU/ml to 10^3 CFU/ml within 30 min and did not recover within 24 h. Xenorhabdus extract (bSBR31.4_TH), on the other hand, increased with the growth of S. aureus strain PB36 (MRSA) was observed over 6–24 h. The controls revealed no reduction in viable count and steady growth throughout 24h. The variabilities of S. aureus strain PB36 (MRSA) was significant difference compared with control at all tested times (p < 0.05). However, the variabilities of S. aureus strain PB36 (MRSA) after exposure to the extract of Photorhabdus strain bSBR31.4_TH at 24 h was no significant differences compared with control (p > 0.05).

**Discussion**

In the present study, the EPNs of six Steinernema surkhetense and two Heterorhabditis indica were isolated from soil samples in Saraburi province, central Thailand, and were identified based on ITS and 28S rDNA sequences. Our finding that S. surkhetense and H. indica were common EPN species found in several provinces of Thailand is consistent with a previous study [16,17]. Fourteen isolates of symbiotic bacteria were identified as X. stockiae (six
Table 1. Antibacterial activity of *Xenorhabdus* and *Photorhabdus* extracts against antibiotic-resistant bacteria as assessed by disk diffusion.

| Bacteria (code) | Inhibit the growth of drug-resistant bacteria<sup>a</sup> |
|----------------|-------------------------------------------------------|
|                | A. baumannii strain AB320 (XDR)<sup>b</sup> | A. baumannii strain AB321 (MDR)<sup>b</sup> | A. baumannii strain AB322 (MDR)<sup>b</sup> | A. baumannii strain AB324 (XDR)<sup>a</sup> | S. aureus strain PB36 (MRSA)<sup>c</sup> | S. aureus strain PB57 (MRSA)<sup>c</sup> | E. coli strain ATCC35218 | E. coli strain PB1 (ESBL and MDR)<sup>d,b</sup> | E. coli strain PB31 (ESBL and CRE)<sup>d,e</sup> | P. aeruginosa strain PB30 (MDR)<sup>b</sup> | E. faecalis ATCC51299 | K. pneumoniae strain B5 (ESBL and MDR)<sup>b</sup> | K. pneumoniae strain PB21 (ESBL and CRE)<sup>d,e</sup> |
| X. stockiae (bSBR4.5_TH) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| P. luminescens subsp. akhurstii (bSBR11.1_TH) | + | + | + | +++ | +++ | +++ | + | - | ++ | - | - | - | + |
| P. luminescens subsp. akhurstii (bSBR12.3_TH) | + | + | + | - | +++ | +++ | ++ | - | - | - | ++ | - | - |
| X. stockiae (bSBR18.3_TH) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| X. stockiae (bSBR19.1_TH) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| X. stockiae (bSBR31.4_TH) | + | + | + | - | ++ | ++ | + | - | - | + | - | - | - |
| P. luminescens subsp. akhurstii (bSBR36.2_TH) | + | + | ++ | + | +++ | +++ | ++ | - | + | + | + | - | - |

<sup>a</sup> Extensively drug resistant
<sup>b</sup> Multidrug resistance
<sup>c</sup> Methicillin resistance *Staphylococcus aureus*, and
<sup>d</sup> Extended spectrum beta-lactamase
<sup>e</sup> Carbapenem-resistant Enterobacteriaceae

https://doi.org/10.1371/journal.pone.0234129.t001
Fig 2. Disk diffusion method of bacterial extracts against three antibiotic-resistant bacteria. Clear zone of *S. aureus* strain PB36 (MRSA; A and B), *A. baumannii* strain AB322 (MDR; C and D), *E. faecalis* ATCC51299 (E and F) after exposure to bacterial extracts from bSBR4.5_TH *X. stockiae* (1) bSBR11.1_TH *P. luminescens* subsp. *akhurstii* (2), bSBR12.1_TH *P. luminescens* subsp. *akhurstii* (3), bSBR18.3_TH *X. stockiae* (4), bSBR19.1_TH *X. stockiae* (5), bSBR31.4_TH *X. stockiae* (6), bSBR36.2_TH *P. luminescens* subsp. *akhurstii* (7), antibiotic disks (P) and negative control (N).

https://doi.org/10.1371/journal.pone.0234129.g002
isolates), *P. luminescens* subsp. *akhurstii* (five isolates), *P. luminescens* subsp. *hainanensis* (two isolates), and *P. asymbiotica* subsp. *australis* (one isolate). Our previous study reported that these bacteria were commonly found in several provinces of Thailand, including Phetchabun, Kanchanaburi, Nakhon Ratchasima, Nakhon Nayok, Khon Kaen, and Suphanburi [16,17].

The different strains of *Xenorhabdus* and *Photorhabdus* have been reported with variation in antibacterial activity. In the present study, four isolates of *Xenorhabdus* and *Photorhabdus*

Table 2. Antibacterial activity of *Xenorhabdus* and *Photorhabdus* extracts against antibiotic-resistant bacteria as assessed by minimum inhibitory concentrations and minimal bactericidal concentration.

| Bacteria (code) | Concentration of inhibition (mg/ml) |
|----------------|-----------------------------------|
|                | *S. aureus* strain PB36 (MRSA) | *S. aureus* strain PB37 (MRSA) | *A. baumannii* strain AB321 (MDR) | *A. baumannii* strain AB322 (MDR) | *E. faecalis* ATCC51299 |
| *P. luminescens* subsp. *akhurstii* (bSBR11.1_TH) | 0.98 | 0.98 | 0.98 | 0.98 | 1.95 | 3.90 | 3.90 | 7.81 |
| *P. luminescens* subsp. *akhurstii* (bSBR12.3_TH) | 0.98 | 0.98 | 0.98 | ND | ND | 3.90 | 7.81 | 3.90 | 7.81 |
| *X. stockiae* (bSBR31.4_TH) | 3.90 | 7.81 | ND | ND | ND | 7.81 | 7.81 | ND | ND |
| *P. luminescens* subsp. *akhurstii* (bSBR36.2_TH) | 0.98 | 0.98 | ND | ND | ND | 3.90 | 3.90 | 1.95 | 3.90 |

ND = Not determined

https://doi.org/10.1371/journal.pone.0234129.t002

Table 3. MIC (mg/ml) and FIC index of Oxacillin and Vancomycin when used either alone or in combination with bacterial extracts against *S. aureus* strain PB36 (MRSA).

| Combination of agents | MIC (mg/ml) in combination (A + B) | FIC index* | Type of interaction |
|----------------------|------------------------------------|------------|--------------------|
| *P. luminescens* subsp. *akhurstii* (bSBR11.1_TH) | 0.0153 | 1 | No interaction |
| Oxacillin | 0.156 | | |
| *P. luminescens* subsp. *akhurstii* (bSBR12.3_TH) | 0.49 | 0.53 | No interaction |
| Oxacillin | 0.0049 | | |
| *X. stockiae* (bSBR31.4_TH) | 0.06125 | 1 | No interaction |
| Oxacillin | 0.156 | | |
| *P. luminescens* subsp. *akhurstii* (bSBR36.2_TH) | 0.49 | 0.53 | No interaction |
| Oxacillin | 0.0049 | | |
| *P. luminescens* subsp. *akhurstii* (bSBR11.1_TH) | 0.0153 | 1 | No interaction |
| Vancomycin | 0.003125 | | |
| *P. luminescens* subsp. *akhurstii* (bSBR12.3_TH) | 0.0153 | 1 | No interaction |
| Vancomycin | 0.003125 | | |
| *X. stockiae* (bSBR31.4_TH) | 0.06125 | 1 | No interaction |
| Vancomycin | 0.003125 | | |
| *P. luminescens* subsp. *akhurstii* (bSBR36.2_TH) | 0.0153 | 1 | No interaction |
| Vancomycin | 0.003125 | | |

*FIC index = FIC A + FIC B, where FIC A is the MIC (mg/ml) of drug A in the combination/MIC of drug A alone, and FIC B is the MIC of drug B in the combination/MIC of drug B alone. The combination is considered synergistic when FICI ≤ 0.5, no interaction when the FICI is 0.5–4.0, and antagonism when the FICI is > 4.0.*

https://doi.org/10.1371/journal.pone.0234129.t003
extracts showed efficacy against many antibiotic-resistant bacteria. *Photorhabdus luminescens* subsp. *akhurstii* (bSBR36.2_TH) extract showed the most inhibitory effect compared with the bacterial isolates tested. The previous study showed that *P. luminescens* could inhibit the growth of *B. subtilis, E. coli, S. pyogenes*, and *S. aureus* RN4220 (drug-resistant and clinical isolate) [10]. *Photorhabdus* can inhibit the growth of up to 32 species of fungi [9]. In addition, trans-cinnamic acid (TCA), produced by *Photorhabdus*, showed the inhibition of *Colletotrichum gloeosporioides, C. fragariae*, and *C. acutatum* at 10–100 μg/ml. This substance also inhibits the growth of *Fusicladium effusum*, which is the cause of Pecan scab [35]. In addition, our study demonstrated that the ethyl acetate extract of bMW27.4_TH *P. temperata* subsp. *temperata* could inhibit up to 10 strains of drug-resistant bacteria. All *Photorhabdus* extracts of Mae Wong national park could inhibit *S. aureus* ATCC20475, *S. aureus* strain PB36 (MRSA), and *S. aureus* strain PB57 (MRSA) [36]. *Xenorhabdus* produced xenocoumacin derivatives [37] and amicoumacin derivatives [38], were found to be potent antibiotics against *S. aureus* [8], while all the *Photorhabdus* spp. produced isopropylstilbene [39,40], which had multiple biological activities, including antibiotic activity against *S. aureus* and *E. coli* [24].

Based on the MIC and MBC, the ability to inhibit the growth of antibiotic-resistant bacteria varied on each isolate of *Xenorhabdus* and *Photorhabdus*. This may be due to either the ability of each symbiotic bacterium to produce effective metabolites or the susceptibility of antibiotic-resistant bacteria. The MIC of *Photorhabdus* extracts on *S. aureus* strain PB36 (MRSA) was found in 0.98 mg/ml in this study. In contrast, the *Stephania suberosa* Forman extract (SSE) against ampicillin-resistant *S. aureus* showed higher MIC with 4 mg/ml [34]. High MIC was also noted in the olive oil polyphenol extract [41], *Camellia sinensis*, and *Azadirachta indica* leaves extracts [42] against *S. aureus*. This indicates that *Photorhabdus* extracts are more effective than SSE, olive oil polyphenol extract, *Camellia sinensis*, and *Azadirachta indica* leaves extracts.

The combination of bacteria extracts and antibiotics (oxacillin and vancomycin) exhibited no synergistic activity against *S. aureus* strain PB36 (MRSA). These results were in contrast with a previous study suggesting that *Stephania suberosa* Forman extract demonstrates synergistic interaction with ampicillin against the clinical isolates of *S. aureus* [34]. Moreover, the
combinations of *Cyperus rotundus* L. extract and ampicillin antibiotics showed a synergistic interaction against *S. aureus* [43].

In terms of time kill assay for *S. aureus* strain PB36 (MRSA), the extracts of bSBR11.1_TH, bSBR12.3_TH, and bSBR36.2_TH had stronger bactericidal activities than extracts of bSBR31.4_TH. This result correlates with the MIC and MBC assays. Moreover, the assay time for killing *S. aureus* strain PB36 (MRSA) was rapidly limited to 30 min. These results differ from the previous findings, wherein *Stephania suberosa* Forman extract plus ampicillin antibiotic exhibited synergistic activity against the ampicillin-resistant *S. aureus* [34]. Apart from this, the combinations of *Cyperus rotundus* L. extract and ampicillin antibiotics showed that the killing of ampicillin-resistant *S. aureus* cells was dramatically reduced by these combinations [43]. Although, mechanism by which the products from *Xenorhabdus* and *Photobacterium* exhibited activity against antibiotic-resistant bacteria is not known. The results from previous studies based on known antibacterial compounds produced from *Xenorhabdus* and *Photobacterium* suggest that the products may inhibit bacterial growth by Xenocoumacins [7], Fabclavines, 1-carbapen-2-em-3-carboxylic acid [10], 2-isopropyl-5-(3-phenyl-2-oxiranyl) benzene-1,3-diol [25]. Confirmation of the mechanism and identification of the specific target on bacterial cell are important for the novel drug discovery. In addition, cytotoxic testing of the novel compounds could be promoting the use of the new drug. At present, a few toxins identified from *Photobacterium* bacteria showed cytotoxicity to mammalian cells [44–46]. This indicates that several concerns of drug recovery need to be seriously considered before use.

In summary, fourteen isolates of EPNs were obtained from a total of 230 soil samples, with 46 soil sites collected from Saraburi province, central Thailand. *Steinernema surkhetense* and *Heterorhabditis indica* were the common species found in soil samples. For symbiotic bacteria, *Xenorhabdus stockiae* (six isolates), *P. luminescens* subsp. *akhurstii* (five isolates), *P. luminescens* subsp. *hainanensis* (two isolates), and *P. asymbiotica* subsp. *australis* (one isolate) were also isolated from EPNs in the Saraburi province. Based on antibacterial activity, *Photobacterium* spp. showed the potential to inhibit the growth of *S. aureus* strain PB36 (MRSA). This finding might be useful in further drug discovery from natural resources.

**Acknowledgments**

We thank Mr. Apirak Miyawong and Mr. Sirawit Kornnithikul, for their assistance in soil collection. We also thank Dr. Sarunporn Tandhavanant for her assistance in statistical analysis. We are grateful to Professor Gavin P. Reynolds, Faculty of Medical Science, Naresuan University who gave comments and assist in editing English on the manuscript.

**Author Contributions**

**Conceptualization:** Paramaporn Muangpat, Apichat Vitta, Aunchalee Thanwisai.

**Data curation:** Paramaporn Muangpat, Apichat Vitta, Aunchalee Thanwisai.

**Formal analysis:** Paramaporn Muangpat, Apichat Vitta, Aunchalee Thanwisai.

**Funding acquisition:** Aunchalee Thanwisai.

**Investigation:** Aunchalee Thanwisai.

**Methodology:** Paramaporn Muangpat, Manawat Suwannaroj, Thatcha Yimthin, Chamaiporn Fukruksa, Sutthirat Sithisak, Narisara Chantratita, Apichat Vitta, Aunchalee Thanwisai.

**Project administration:** Aunchalee Thanwisai.

**Resources:** Apichat Vitta, Aunchalee Thanwisai.
Software: Aunchalee Thanwisai.
Supervision: Aunchalee Thanwisai.
Validation: Aunchalee Thanwisai.
Visualization: Aunchalee Thanwisai.
Writing – original draft: Paramaporn Muangpat, Manawat Suwannaroj, Thatcha Yimthin, Chamaiporn Fukruksa, Sutthirat Sitthisak, Narisara Chantratita, Apichat Vitta, Aunchalee Thanwisai.
Writing – review & editing: Paramaporn Muangpat, Manawat Suwannaroj, Thatcha Yimthin, Chamaiporn Fukruksa, Sutthirat Sitthisak, Narisara Chantratita, Apichat Vitta, Aunchalee Thanwisai.

References
1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKEAPE. J Infect Dis. 2018; 197: 1079–1081.
2. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging Strategies to Combat ESKEAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front Microbiol. 2019; 10: 539. https://doi.org/10.3389/fmicb.2019.00539 PMID: 30988689
3. Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents. 2013; 42: S25–8. https://doi.org/10.1016/j.ijantimicag.2013.04.007 PMID: 23684003
4. Queenan K, Häslar B, Rushton J. A One Health approach to antimicrobial resistance surveillance: is there a business case for it?. J Antimicrob Agents. 2016; 48(4): 422–7.
5. Roe VA. Antibiotic resistance: a guide for effective prescribing in women’s health. J Midwifery Womens Health. 2018; 53: 216–226.
6. Chokshi A, Sifri Z, Cennimo D, Horng H. Global Contributors to Antibiotic Resistance. J Glob Infect Dis. 2019; 11: 36–42. https://doi.org/10.4103/jgid.jgid_110_18 PMID: 30814834
7. McInerney BV, Taylor WC, Lacey MJ, Akhurst RJ, Gregson RP. Biologically active metabolites from *Xenorhabdus* spp., Part 2. Benzopyran-1-one derivatives with gastroprotective activity. J Nat Prod. 1991; 54: 785–795. https://doi.org/10.1021/np50075a006 PMID: 1955881
8. Bode HB. Bacteria as a source of secondary metabolites. Curr Opin Chem Biol. 2009; 13: 224–230. https://doi.org/10.1016/j.cbpa.2009.02.037 PMID: 19345136
9. Chen G. Antimicrobial Activity of the Nematode Symbionts, *Xenorhabdus* and *Photorhabdus* (Enterobacteriaceae), and the Discovery of Two Groups of Antimicrobial Substances, Nematophilin and Xenorxides. In: Canada (Doctoral dissertation). British Columbia: Simon Fraser University; 1996.
10. Derzelle S, Duchaud E, Kunst F, Danchin A, Bertin P. Identification, Characterization, and Regulation of a Cluster of Genes Involved in Carbapenem Biosynthesis in *Photorhabdus luminescens*. Appl Environ Microbiol. 2002; 68: 3780–3789. https://doi.org/10.1128/aem.68.8.3780-3789.2002 PMID: 12147472
11. Bock CH, Shapiro-Ilan DI, Wedge DE, Cantrell CL. Identification of the antifungal compound, trans-cinnamic acid, produced by *Photorhabdus luminescens*, potential biopesticide against pecan scab. J Pest Sci. 2014; 87: 155–162.
12. Ullah I, Khan AL, Ali L, Khan AR, Waqas M, Hussain J, et al. Benzaldehyde as an insecticidal, antimicrobial, and antioxidant compound produced by *Photorhabdus temperate* M1021. J Microbiol. 2015; 53: 127–133. https://doi.org/10.1007/s12275-015-4632-4 PMID: 25626368
13. Kaya HK, Gaugler R. Entomopathogenic nematodes. Annu. Rev. Microbiol. 1993; 38: 181–206.
14. Tailliez P, Pages S, Ginibre N, Boemare N. New insight into diversity in the genus *Xenorhabdus*, including the description of ten novel species. Int J Syst Evol Microbiol. 2006; 56: 2805–2818. https://doi.org/10.1099/ijs.0.64287-0 PMID: 17158981
15. Maneesakom P, Grewal PS, Chandrapaty A, Steinerema minutum sp. nov. (Rhabditida: Steinernematidae): a new entomopathogenic nematode from Thailand. Int J Nematol. 2010; 20: 27–42.
16. Thanwisai A, Tandhavanant S, Saiprom N, Waterfield NR, Long PK, Bode HB, et al. Diversity of *Xenorhabdus* and *Photorhabdus* spp. and Their Symbiotic Entomopathogenic Nematodes from Thailand. PLoS ONE. 2012; 7: e43835. https://doi.org/10.1371/journal.pone.0043835 PMID: 22984446
17. Vitta A, Fukrukja C, Yimthin T, Deelue K, Sarai C, Polseela R. Preliminary survey of entomopathogenic nematodes in upper northern Thailand. Southeast Asian J Trop Med Public Health. 2017; 48: 18–26. PMID: 29644816
18. Adams BJ, Fodor A, Koppenhöfer HS, Stackebrandt E, Stock SP, Klein MG. Biodiversity and systematics of nematode bacterium entomopathogens. Biol Cont. 2006; 37: 32–49.

19. Bhat AH, Istkhar, Charubey AK, Püza V, San-Blas E. First Report and Comparative Study of Steinernema surkhetense (Rhabditidae: Steinernematidae) and its Symbiotic Bacteria from Subcontinental India. J Nematol. 2017; 49(1): 92–102. https://doi.org/10.21307/jofnem-2017-049 PMID: 28512381

20. Cimen H, Lee MM, Hatting J, Hazir S, Stock SP. Steinernema tophus sp. n. (Nematoda: Steinernematidae), a new entomopathogenic nematode from South Africa. Zootaxa. 2014; 3821: 337–353. https://doi.org/10.11646/zootaxa.3821.3.3 PMID: 24989748

21. Malan AP, Knoetz R, Tiedt L. Heterorhabditis noeniputentis n. sp. (Rhabditida: Heterorhabditidae), a new entomopathogenic nematode from South Africa. J Helminthol. 2014; 88: 139–151. https://doi.org/10.1017/S0022149X12000806 PMID: 23232041

22. Nthenga I, Knoetz R, Berry S, Tiedt LR, Malan AP. Steinernema sacchari n. sp. (Rhabditida: Steinernematidae), a new entomopathogenic nematode from South Africa. J Nematol. 2014; 16: 475–494.

23. Phan KL, Mráček Z, Půza V, Nermut J, Jarosňová A. Steinernema huense sp. n., a new entomopathogenic nematode (Nematoda: Steinernematidae) from Vietnam. J Nematol. 2014; 16: 761–775.

24. Shi D, An R, Zhang W, Zhang G, Yu Z. Stilbene Derivatives from Hypoxylon murorum. Med Chem. 2006; 14: 4677–468. https://doi.org/10.1016/j.bmc.2006.01.025 PMID: 16644226

25. Grundmann F, Kaiser M, Schiell M, Batzer A, Kurz M, Thanwisaï A, et al. Antiparasitic Chaiyaphumines from entomopathogenic Xenorhabdus sp. PB61.4. J Nat Prod. 2014; 77: 779–783. https://doi.org/10.1021/acs.jnatprod.1004303 PMID: 27960253

26. Food and Drug Administration. Announcing Food and Drug Administration Blogs. 2018 Apr 01 [cited 13 Apr 2020]. In: Food and Drug Administration Blogs [Internet]. United States. Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process.

27. Bedding RA, Akhurst RJ. A simple technique for the detection of insect parasitic rhabditid nematode in soil. Nematologica. 1975; 21: 109–110.

28. White GF. A method for obtaining infective nematode larvae from cultures. Science. 1927; 66: 302–303.

29. Hominick WM, Briscoe BR, Del Pino FG, Heng J, Hunt DJ, Kozodoi E, et al. Biosystematics of entomopathogenic nematodes: current status, protocols and definitions. J Helminthol. 1997; 71: 271–298. https://doi.org/10.1017/s0022149x00016096 PMID: 9443947

30. Stock SP, Campbell JF, Nadler SA. Phylogeny of Steinemema Travassos 1927 (Cephalobina: Steinernematidae) inferred from ribosomal DNA sequences and morphological characters. J Parasitol. 2001; 87: 877–889. https://doi.org/10.1645/0022-3395[2001]087[0877:POSTC]2.0.CO;2 PMID: 11534654

31. Tailliez P, Laroui C, Ginibre N, Paule A, Pajès S, Boemare N. Phylogeny of Photorhabdus and Xenorhabdus based on universally conserved protein-coding sequences and implications for the taxonomy of these two genera. Int J Syst Evol Microbiol. 2010; 60: 1921–1937. https://doi.org/10.1099/ijs.0.014308-2 PMID: 19783607

32. Seier-Petersen MA, Jasiu A, Arestrup FM, Vigne H, Mullany P, Roberts AP, et al. Effect of subinhibitory concentrations of four commonly used biocides on the conjugative transfer of Tn916 in Bacillus subtilis. J Antimicrob Chemother. 2014; 69: 343–348. https://doi.org/10.1093/jac/dkt370 PMID: 24092655

33. Muangpat P, Yooyangkiet T, Fukunaka C, Suwannaraj M, Yimthin T, Sitthisak S, et al. Screening of the Antimicrobial Activity against Drug Resistant Bacteria of Photorhabdus and Xenorhabdus Associated with Entomopathogenic Nematodes from Mae Wong National Park, Thailand. Front Microbiol. 2017; 8: 1142. https://doi.org/10.3389/fmicb.2017.01142 PMID: 28702004

34. Shapiro-Ilan DI, Han R, Qiu X. Production of entomopathogenic nematodes. In: Morales-Ramos J, Rojas G, and Shapiro-Ilan DI editors. Mass production of beneficial organisms: Invertebrates and entomopathogens, San Diego CA: Academic Press; 2014. pp. 321–356

35. Reimer D, Luxenburger E, Brachmann AO, Bode HB. A new type of pyrrolidine biosynthesis is involved in the late steps of Xenomoumacin production in Xenorhabdus nematophila. ChemBioChem. 2009; 10: 1997–2001. https://doi.org/10.1002/cbic.200900187 PMID: 19598185
38. Park H, Perez C, Perry E, Crawford JM. Activating and attenuating the amicoumacin antibiotics. Molecules. 2016; 21: E824.

39. Li J, Chen G, Wu H, Webster JM. Identification of two pigments and a hydroxystilbene antibiotic from Photorhabdus luminescens. Appl Environ Microbiol. 1995; 61: 4329–4333. PMID: 8534100

40. Buscató EL, Büttner D, Brüggerhoff, Klingler FM, Weber J, Scholz B, et al. From a multipotent stilbene to soluble epoxide hydrolase inhibitors with antiproliferative properties. ChemMedChem. 2013; 8: 919–923. https://doi.org/10.1002/cmdc.201300057 PMID: 23596124

41. Guo L, Gong S, Wang Y, Sun Q, Duo K, Fei P. Antibacterial Activity of Olive Oil Polyphenol Extract Against Salmonella Typhimurium and Staphylococcus. Foodborne Pathog Dis. 2019. https://doi.org/10.1089/fpd.2019.2713.

42. Zihadi MAH, Rahman M, Talukder S, Hasan MM, Nahar S, Sikder MH. Antibacteria efficacy of ethanolic extract of Camellia sinensis and Azadirachta indica leaves on methicillin-resistant Staphylococcus aureus and shiga-toxigenic Escherichia coli. J Adv Vet Anim Res. 2019; 6(2): 247–252. https://doi.org/10.5455/javar.2019.f340 PMID: 31453199

43. Cheypratub P, Leeansaksiri W, Eumkeb G. The Synergy and Mode of Action of Cyperus rotundus L. Extract Plus Ampicillin against Ampicillin-Resistant Staphylococcus aureus. Evid Based Complement Alternat Med. 2018; 2018: 3438453. https://doi.org/10.1155/2018/3438453 PMID: 29849704

44. Zhang X, Hu X, Li Y, Ding X, Yang Q, Sun Y, et al. XaxAB-like binary toxin from Photorhabdus luminescens exhibits both insecticidal activity and cytotoxicity. FEMS Microbiol Lett. 2014; 350(1): 48–56. https://doi.org/10.1111/1574-6968.12321 PMID: 24188660

45. Li Y, Hu X, Zhang X, Liu Z, Ding X, Xia L, et al. Photorhabdus luminescens PirAB-fusion protein exhibits both cytotoxicity and insecticidal activity. FEMS Microbiol Lett. 2014; 356(1): 23–31. https://doi.org/10.1111/1574-6968.12474 PMID: 24840022

46. Sun Y, Zhang G, Hou X, Xiao S, Yang X, Xie Y, et al. SrfABC Toxin from Xenorhabdus stockiae Induces Cytotoxicity and Apoptosis in HeLa Cells. Toxins (Basel). 2019; 11(12). pii: E685.